A phase 2 clinical trial has demonstrated that pomalidomide, used to treat bone marrow cancer, is safe and effective for managing hereditary hemorrhagic telangiectasia, a rare genetic bleeding ...

The New England Journal of Medicine published the trial results, which show that patients with HHT who were administered the ...

Bone marrow cancer drug shows success in treatment of rare blood disorder: Study: Bethesda, Maryland Friday, September 20, 2024, 16:00 Hrs [IST] A clinical trial supported by the ...

A clinical trial was stopped early after researchers found that a bone marrow cancer drug, is safe and effective for treating ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of ...

A trial found the drug pomalidomide effectively treats hereditary hemorrhagic telangiectasia (HHT), reducing nosebleeds and ...

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

Learn about how Pomalidomide, a cancer drug, shows promise in treating hereditary hemorrhagic telangiectasia (HHT), a rare ...